Physician profile
Azra Abdullah
NPI 1063468916
$2,198.60
in general payments reported to CMS, 2019-2025
25 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $288 · 2021: $11.88 · 2022: $13.70 · 2023: $103 · 2024: $398 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $457.38 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $261.93 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $225.37 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $193.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $124.58 | 2019-2020 | |
| Pfizer INC. | $119.61 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $116.84 | 2019-2024 | |
| Amgen INC. | $89.47 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $85.44 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $75.69 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $72.03 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.53 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $42.36 | 2024 | |
| Merck Sharp & Dohme LLC | $40.94 | 2019-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Dexcom, INC. | $36.80 | 2024-2025 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $26.93 | 2019 | |
| Abbvie INC. | $26.23 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $24.00 | 2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $23.95 | 2025 | Fanapt |
| Dynavax Technologies Corporation | $22.72 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $22.22 | 2024 | Voquezna |
| Abbott Laboratories | $19.06 | 2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $15.99 | 2024 | Xyosted |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azra Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.